Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Travere Therapeutics Inc Common Stock (TVTX).
- Disclosed ownership: 5.6%.
- Date of event: 31 Mar 2025.
VANGUARD GROUP INC - 31 Mar 2025 SCHEDULE 13G/A Report for Travere Therapeutics Inc Common Stock (TVTX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- TVTX
- Shares outstanding
- 88,743,717 shares
- Disclosed Ownership
- 5,014,020 shares
- Ownership
- 5.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 Apr 2025, 11:22:38 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 31 Jan 2025
- Next filing
- 29 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 5.6% ownership in Travere Therapeutics Inc Common Stock (TVTX) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 31 Jan 2025.
- Current filing was accepted on 30 Apr 2025, 11:22.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 5.6% | 5,014,020 | 0 | 60,006 | Ashley Grim | Head of Global Fund Administration |